Scholarlink

Background <p>Since 2023, two preventive tools (monoclonal antibodies, nirsevimab, and preF maternal vaccine) were approved to protect infants against severe RSV infections. During winter 2024–2025, nirsevimab started to be administered in Belgium to infants &lt; 6 months old encountering their first RSV season. We aim to evaluate on a national scale the impact of RSV prevention in the pediatric hospital setting.</p> Method <p>This survey pooled data from two surveillance systems: the prospective SARI (Severe Acute Respiratory Infection) surveillance (6 hospitals) and the retrospective RSVPed study (25 hospitals). Both used the same case definition and clinical questionnaire to record RSV hospitalizations in children &lt; 5 years. Seasonal incidences and clinical data were compared between seasons 2023–2024 (pre-prevention) and 2024–2025 (first year of prevention).</p> Results <p>Our study covered 47% of all pediatric beds in Belgium. We demonstrated a reduction of 39% in pediatric RSV-related hospitalizations and of 57% in RSV-related admissions to intensive care units during 2024–2025 compared to 2023–2024. Incidences decline mainly concerned infants &lt; 6 months, without changes in older age groups. Furthermore, savings in health care resources were observed through shorter length of stay and significantly less use of non-invasive ventilatory support and nutritional support among hospitalized cases in 2024–2025.</p> Conclusion <p>Following implementation of nirsevimab, a substantial reduction in RSV paediatric burden was observed in Belgium. However, efforts should be made to increase the uptake of preventive tools in our country to achieve better effectiveness. This study also highlights the major role of a national network to monitor efficacy of prevention over time.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

National real-life impact of prevention with nirsevimab on infants’ RSV hospitalizations in Belgium

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月20日

查看全文
  • Sophie Blumental,
  • Adrien Lajot,
  • Mathil Vandromme,
  • Yves Lafort,
  • Yinthe Dockx,
  • Sarah Denayer,
  • Alicia Wampers,
  • Andrea Nebbioso,
  • Anne Tilmanne,
  • Celine Mignon,
  • David Tuerlinckx,
  • Hanne Rigolle,
  • Inge Matthijs,
  • Jan Vandersnickt,
  • Johan Hellinckx,
  • Jonas Dewulf,
  • Katrien Coppens,
  • Kim Van Hoorenbeeck,
  • Koen Vanlede,
  • Lore Winters,
  • Lucie Seyler,
  • Marie-Pierre Parsy,
  • Marijke Reynders,
  • Mathilde Balcaen,
  • Montse Urbina,
  • Nicolas Dauby,
  • Olga Chatzis,
  • Reinout Naesens,
  • Sarah Dorval,
  • Silke Ternest,
  • Sophie Vanspeybroeck,
  • Tessa Goetghebuer,
  • Tine Van Ackere,
  • Valbona Selimaj Kontoni,
  • Wassim El Bitar,
  • Xavier Holemans,
  • Yveline Bruyere,
  • Daan Van Brusselen,
  • Laurane De Mot,
  • Marc Raes

摘要

Background

Since 2023, two preventive tools (monoclonal antibodies, nirsevimab, and preF maternal vaccine) were approved to protect infants against severe RSV infections. During winter 2024–2025, nirsevimab started to be administered in Belgium to infants < 6 months old encountering their first RSV season. We aim to evaluate on a national scale the impact of RSV prevention in the pediatric hospital setting.

Method

This survey pooled data from two surveillance systems: the prospective SARI (Severe Acute Respiratory Infection) surveillance (6 hospitals) and the retrospective RSVPed study (25 hospitals). Both used the same case definition and clinical questionnaire to record RSV hospitalizations in children < 5 years. Seasonal incidences and clinical data were compared between seasons 2023–2024 (pre-prevention) and 2024–2025 (first year of prevention).

Results

Our study covered 47% of all pediatric beds in Belgium. We demonstrated a reduction of 39% in pediatric RSV-related hospitalizations and of 57% in RSV-related admissions to intensive care units during 2024–2025 compared to 2023–2024. Incidences decline mainly concerned infants < 6 months, without changes in older age groups. Furthermore, savings in health care resources were observed through shorter length of stay and significantly less use of non-invasive ventilatory support and nutritional support among hospitalized cases in 2024–2025.

Conclusion

Following implementation of nirsevimab, a substantial reduction in RSV paediatric burden was observed in Belgium. However, efforts should be made to increase the uptake of preventive tools in our country to achieve better effectiveness. This study also highlights the major role of a national network to monitor efficacy of prevention over time.

Clinical trial number

Not applicable.